According to the latest financial report of X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B, the latest earnings per share (TTM) for the company is --. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B's free cash flow? The latest report shows it as -34.12M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B shows that the company's current ratio is 4.89, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B, the quick ratio is 4.65, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B? The latest ROE figure is -47.63%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B, the total asset return on investment (ROA) is -18.88%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B's latest financial report to see how their gross margin is doing - currently at 59.46%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of X4 PHARMACEUTICALS INC C/WTS 29/11/2024(TO PUR COM) CL B, the net profit margin is -6.55K%, which is a good sign for its profitability.